Search results for "Disease course"

showing 4 items of 24 documents

COVID-19 y tabaquismo: revisión sistemática y metaanálisis de la evidencia

2021

RESUMEN Objetivo: el objetivo del estudio ha sido responder a las siguientes preguntas: ¿Se asocia el consumo de tabaco en pacientes con Covid-19 con una progresión negativa y desenlace adverso de la enfermedad? y, ¿se asocia el consumo de tabaco, actual y pasado, a una mayor posibilidad de desarrollar COVID-19? Material y Métodos: Se realizó una revisión sistemática (RS) y metaanálisis (MA) de trabajos publicados previamente. La estrategia de búsqueda incluyó todos los descriptores conocidos sobre Covid-19 y tabaco y se realizó en diferentes bases de datos. Se utilizaron modelos estadísticos adecuados para abordar el tamaño del efecto en un metaanálisis: modelo de efectos aleatorios y de e…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industrymedicine.medical_treatmentSmokingOdds ratioPublication biasFixed effects modelRandom effects modelFormer SmokerArticleDisease courseMeta-analysis03 medical and health sciences0302 clinical medicine030228 respiratory systemInternal medicineSystematic reviewmedicineIntubationObservational studyRisk factorCovid-19businessArchivos de Bronconeumología
researchProduct

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients

2014

The advent of biologic medications has considerably increased the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.

juvenile idiopathic arthritis etanerceptmedicine.medical_specialtyPediatricsbusiness.industryAlternative medicineArthritismedicine.diseaseRheumatologyEtanerceptDisease courseSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicinePoster PresentationPediatrics Perinatology and Child HealthPhysical therapymedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child Healthbusinessmedicine.drug
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Standard Therapeutic Approach and New Therapies

2015

The traditional approach to therapy of Crohn’s disease has been the step-up approach usually represented as a pyramid (Fig. 7.1) where, progressing from mild to severe disease, therapeutic choices proceed step by step from less potent drugs at the basement of the pyramid to more potent but also more toxic drugs at the top. The advent of biological therapies and the wider use of immunomodulators, together with the opportunity to achieve ambitious treatment goals and possibly to modify the course of disease, have led to other approaches such as the accelerated step-up or the top-down approach. This means that immunomodulators and biologics can be used earlier and de-escalated when disease is …

medicine.medical_specialtybusiness.industryProgressive multifocal leukoencephalopathyfood and beveragesSevere diseaseDiseaseTreatment goalsmedicine.diseaseDisease courseTherapeutic approachPyramidMedicineCertolizumab pegolbusinessIntensive care medicinemedicine.drug
researchProduct